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Although a variety of medications are used in 
the treatment of Parkinson's disease, all have 
short term effects. As a result, motor 
performance varies over time. A key role of the 
physiotherapist is to measure fluctuations in 
the severity of movement disorders in relation 
to the dose and timing of anti-Parkinsonian 
medication with a view to: (i) optimising motor 
performance; (ii) targeting therapeutic 
interventions for times of greatest need; and 
(iii) communicating findings to the inter-
professional team. For an informed approach to 
the measurement of medication-induced motor 
fluctuations, clinicians require an ur.derstanding 
of the pathophysiology of Parkinson's disease, 
the mode of action of medications and the 
validity of existing methods used to quantify 
changes in performance resulting from 
pharmaceuticals and rehabilitation. 
[Morris M. lansek R and Churchyard A: The role 
of the physiotherapist in quantifying movement 
fluctuations in Parkinson's disease. Australian 
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The role of the physiotherapist 
in quantifying movement 
fluctuations in 
Parkinson's disease 
arkinson's disease is a chronic 
neurological condition that leads 
to a progressive decline in motor 
performance as well as cognitive 
impairment. It affects at least 1 per 
cent of people over 75 years of age 
(Schoenberg 1987). Therefore it can 
be estimated that more than 30,000 
Australians currently suffer from 
Parkinson's disease. With the rapid 
population ageing throughout 
industrialised countries, there has been 
a sharp increase in the demand for 
effective medical and physiotherapy 
services for people with this disabling 
condition. 
·Because the cause of Parkinson's 
disease is not yet known, treatment is 
currently symptomatic. The disease 
affects the ability to perform well-
learned movement sequences such as 
walking, writing, reaching and 
grasping, dressing and swallowing, 
hence treatment aims to reduce the 
severity of movement disorders that 
compromise these functions. The 
classic movement disorders that are 
observed in people with Parkinson's 
disease are: 
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• hypokinesia - reduced movement 
speed and amplitude (poverty of 
movement); 
• akinesia - difficulty initiating 
movement; motor blocks during 
movement; 
• tremor - usually resting tremor 
although can present as postural 
tremor; 
• rigidity - increased stiffness which 
can be detected during passive 
movement testing; 
• postural instability - defective 
proactive and reactive balance 
control mechanisms; and 
• dyskinesia - involuntary extra 
movements including chorea and 
dystonia which occur in end-stage 
disease. 
These movement disorders arise due 
to a progressive loss of neurones in the 
substantia nigra located in the 
midbrain that normally produce the 
neurotransmitter dopamine. Dopamine 
is used in conjunction with other 
neurotransmitters to enable the basal 
ganglia to control movement. As 
illustrated in Figure 1, the basal 
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Table 1. Medication used in the treatment of Parkinson's disease* 
Type of Drug Aim Generic Name Example of Potential 
Brand Names Side Effects 
1. Dopamine Dopamine replacement Levodopa carbidopa Sinemet Nausea 
Precursors therapy: boosts the Kinson Light headedness 
production of dopamine Levodopa benserazide Madopar Confusion 
in remaining substantia Hallucinations 
nigra cells Paranoia 
2. Dopaminergic Mimic or replicate the Apomorphine Apomorphine Nausea 
Agonists action of dopamine by Cabergoline Cabergoline Vomiting 
stimulating Dl or D2 Confusion 
receptors in the striatum Bromocryptine Parlodel Postural 
Mesylate Kripton hypotension 
Hallucinations 
Pergolide Permax 
Mesylate 
Lysuride Lisuride 
3. Anticholinergics Reduce the relative Benzhexol Artane Visual disturbance 
increase in acetylcholine Hydrochloride Akineton Cognitive 
in proportion to dopamine Orphenadrine Disipal impairment 
in the basal ganglia Hydrochloride Confusion and 
Benztropine Mesylate Cogentin hallucinations in 
Procyclidine Kemadrin elderly people 
Hydrochloride Urinary retention 
Dry mouth 
4. Adamantane Enhance the action of Amantadine Symmetrel Urinary retention 
Derivatives levodopa; glutamate Hydrochloride Ankle oedema 
blockers; may offer Dizziness 
neuroprotection Confusion and 
hallucinations in 
elderly people 
Orthostatic 
hypotension 
5. MAOB Enhance the action of Selegiline Deprenyl Nausea 
Inhibitors levodopa; block the Hydrochloride Eldepryl Vomiting 
breakdown of dopamine. Postural 
May reduce the rate hypotension 
of loss of substantia nigra Confusion and 
cells (neuroprotective effect) hallucinations 
* Adapted from Reynolds EF (1996): The Extra Pharmacopoeia. (31 st ed.) London: The Pharmaceutical Press 
ganglia are a group of subcortical 
nuclei located deep within the brain. 
They are comprised of the substantia 
nigra, the caudate nucleus and 
putamen (together known as the 
striatum), the globus pallidus and the 
subthalamic nucleus. The putamen and 
postero-ventral globus pallidus form 
the motor part of the basal ganglia, 
whereas the caudate nucleus and the 
antero-dorsal globus pallidus play 
more of a role in cognition (DeLong 
1993). 
The major input projections to the 
basal ganglia are the motor and non-
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Table 2. Long and short acting levodopa preparations 
Generic Name Short Acting Preparation 
(Brand name) 
Long Acting Preparation 
(Brand name) 
Other Preparations 
Liquid Levodopa 
Levodopa carbidopa Sinemet 100125 
Sinemet 25012 5 
Sinecarb 100110 
Sinecarb 100125 
Sinecarb 250125 
Kinson 10012 5 
Sinemet M 100/10 
Sinemet CR 200/50 
Levodopa benzeraside Madopar 200/50 
Madopar M 10012 5 
Madopar Q 50/12.5 
Madopar HBS 100125 
motor areas of the cerebral cortex and 
the thalamus. The major output 
projections are via the thalamus to the 
motor cortical regions such as the 
supplementary motor area, premotor 
area and primary motor cortex (Iansek 
et alI995). Figure 1 illustrates the 
cortico-basal ganglia-cortex motor 
loop which regulates the performance 
of motor skills. Within this feedback 
loop there are two motor circuits 
(Alexander and Crutcher 1990). The 
"direct" pathway travels from the 
putamen to the internal globus 
pallidus, substantia nigra pars reticulata 
and then the thalamus. The "indirect" 
pathway travels from the putamen to 
the external globus pallidus and 
subthalamic nucleus before reaching 
the internal globus pallidus, substantia 
nigra pars reticulata and thalamus. 
Normally there is a delicate balance 
between the activity of the direct and 
indirect pathways which allows 
movements to be performed smoothly, 
quickly and easily. In Parkinson's 
disease it is thought that under-activity 
of the direct pathway leads to 
hypokinesia whereas over-activity of 
the indirect pathway is associated with 
dyskinesia. 
The basal ganglia utilise a range of 
different neurotransmitters to regulate 
movement. Dopamine is manufactured 
by substantia nigra neurones and binds 
to and activates D1 and D2 receptors 
in the striatum (Figure 1). Within the 
striatum, GABA is a major 
neurotransmitter for the striatal 
GABA 
Dyn()tplili:l 
SubSta1ice P 
GP/SNpr (Inhibitory) 
Figure 1. Basal ganglia motor loop 
involved in the control of complex 
movement sequences. Sf\lpr - substantia 
nigra pars reticulata; Sl\Ipc - substantia 
nigra pars compacta; Gil e - globus pallidus 
exterrms; GPj - globus pamdus interims; 
STN - subthalamic nucleus. Adapted from 
Delong (1993, p.6) (Figure 1), ill Memo 1\1, 
Hamada i, lJel..01l9 ME: Role of cerebellum 
and basal ganglia in voluntary movement, 
with kind permission from Elsevier 
Science, Amsterdam. 
(Sinemet 100125 
or Kinson 10012 5 
dissolved with ascorbic 
acid mixed into solution 
with water) 
projection neurones, although 
dynorphin, substance P and enkephalin 
co-localise with GABA in the striatal 
projection neurones. Acetylcholine is a 
neurotransmitter used by 
interneurones. It is thought that a 
relative excess of acetylcholine in 
comparison with dopamine is critical in 
creating symptoms of Parkinson's 
disease (Nutt 1987). The pathway from 
the subthalamic nucleus to the internal 
globus pallidus and substantia nigra is 
mainly activated by glutamate 
(DeLong 1993). People with 
Parkinson's disease typically have a 
cluster of neurotransmitter 
disturbances which include a marked 
reduction in dopamine together with a 
relative increase in acetylcholine and 
glutamate. 
Because Parkinson's disease is 
progressive, loss of dopamine 
producing neurones in the substantia 
nigra continues over time. The reason 
why this progressive cell death occurs 
is currently not known. One possible 
explanation is that oxidation of the cell 
membranes and mitochondria of 
substantia nigra neurones occurs due 
to an excessive accumulation of free 
radicals in the brain (Y oudim and 
Riederer 1997). Free radicals are large 
molecules that have an unpaired 
electron. It is hypothesised that they 
acquire electrons from cellular 
structures in the substantia nigra, 
leading to oxidation and cell death 
(Y oudim and Riederer 1997). Despite 
the use of medications such as 
Table 3 continued. 
• Rigidity 
• Tremor 
• Postural 
Test 
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Investigators 
Not reported 
Not reported 
Smithson et al (1998); 
Reliability and Validity 
Not reported 
Not reported 
Instability 
Passive movement 
Visual observation 
Steady Stance Tests: feet 
apart; feet together; 
single limb; tandem; 
step stance 
Hill et al (1996a and 1996b) 
Retest reliability confirmed 
for steady stance tests, 
functional reach and Pastor 
test (Smithson et al 1998) 
and for elderly and stroke 
subjects (Hill et al 1996a 
and 1996b) 
• Dyskinesia 
Proactive control: 
arm raises, step test, functional 
reach 
Reactive control: 
sternal push 
Pastor test 
Visual observation 
Smithson et al (1998) 
Pastor et al (1996) 
Dyskinesia subsection 
UPDRS Iansek (1997) 
Not reported 
refer to Morris, Churchyard 
and Iansek (1998) 
levodopa to redress neurotransmitter 
imbalances, cell death in the substantia 
nigra continues. Eventually, in patients 
with end-stage disease, insufficient 
cells remain in the substantia nigra 
which are able to convert levodopa to 
dopamine; the duration of the response 
to levodopa shortens and motor 
fluctuations develop. Motor 
fluctuations are unpredictable changes 
in movement characterised by periods 
of akinesia and hypokinesia 
interspersed with bouts of dyskinesia 
(Iansek et al 1997). The unpredictable 
response to levodopa makes 
management difficult for the physician 
and frustrating for the patient. For 
these reasons, physiotherapy is usually 
provided in conjunction with 
medication, to teach people strategies 
to move more easily when motor 
fluctuations inevitably occur. 
Parkinson's disease 
medications 
Medications used in the treatment of 
movement disorders in Parkinson's 
disease can be categorised into five 
major groups, based on the 
neurotransmitter imbalances they 
target and their role in preventing cell 
death (Table 1). These include 
medications that: 
(1) boost the production of the 
neurotransmitter dopamine; 
(2) mimic the effects of dopamine by 
stimulating dopamine receptor 
sites in the striatum; 
(3) reduce the acetylcholine imbalance 
in the striatum; 
(4) block over-activity of the 
neurotransmitter glutamate; and 
(5) p:ovide protection for substantia 
mgra neurones. 
(1) Drugs that boost the production of the 
neurotransmitter dopamine 
Levodopa preparations such as 
levodopa-carbidopa (Sinemet, Kinson) 
and levodopa-benserazide (Madopar) 
p'rovide the mainstay of 
pharmacological treatment for 
Parkinson's disease. Levodopa is 
converted into dopamine by dopa-
decarboxylase in the brain, blood, gut, 
liver and muscle. Dopamine cannot be 
used directly by the basal ganglia, as it 
cannot cross the blood-brain barrier 
and is metabolised in peripheral 
regions such as the liver. In contrast, 
levodopa is able to cross the walls of 
selected blood vessels that allow 
transport of chemicals to the central 
nervous system (CNS), and then is 
converted to dopamine by viable 
substantia nigra cells (Cotzias et al 
1969). The high dose of levodopa 
forces substantia nigra neurones to 
increase production of dopamine. 
Microglia and to a lesser extent 
astrocytes in the striatum can also 
convert levodopa into dopamine. 
Levodopa preparations always include 
a peripheral decarboxylase-inhibitor 
(such as carbidopa or benserazide) to 
minimize metabolism of this 
compound in the periphery. To help 
control for shortened drug effects, 
controlled release preparations of 
levodopa such as Sinemet CR and 
Madopar RBS are now available that 
provide moderate stabilisation of 
plasma levodopa levels and have longer 
lasting effects (Table 2) (Nutt 1987). 
Levodopa provides good 
symptomatic relief for approximately 
5-8 years (Jankovic and Marsden 
1988). After that time, it becomes less 
and less effective; the response 
amplitude remains the same although 
the duration of the effect shortens. 
This is due in part to fewer cells 
available in the substantia nigra to 
covert levodopa into dopamine. 
(2) Dopamine agonists 
Dopamine agonist drugs mimic the 
action of dopamine by directly 
stimulating the Dl and D2 receptor 
sites in the striatum. They are also 
thought to boost the uptake of 
dopamine in the striatum by 
stimulating presynaptic receptors 
(Jankovic and Marsden 1988). Most 
frequently used are the D2 agonists 
bromocryptine (Parlodel, Kripton) and 
pergolide (Permax). 
• 
Apomorphine is used in those people 
with severe motor fluctuations arising 
from Parkinson's disease. It acts as a 
dopamine agonist on both the D 1 and 
D2 striatal receptors (Metman et al 
1997) and is prescribed in conjunction 
with domperidone in order prevent 
nausea and vomiting. Apomorphine is 
administered parentally with a 
continuous infusion pump or by 
subcutaneous injection. Subcutaneous 
apomorphine takes approximately 5-10 
minutes to take effect and lasts for 
around 90 minutes. 
(3) Drugs that reduce the activity of 
acetylcholine within the striatum 
As early as 1867, physicians had noted 
that patients with the "shaking palsy" 
showed some improvement in resting 
tremor when they ingested extracts 
from the belladonna nightshade plant 
(Jankovic and Marsden 1988). This 
extract was later found to contain anti-
cholinergic agents which inhibited the 
relative over-activity of acetylcholine 
in the striatum. Normally, in healthy 
elderly people, dopamine levels are 
sufficiently high to counter the natural 
effects of acetylcholine in the caudate 
and putamen. In people with 
Parkinson's disease, however, the 
reduction in striatal dopamine leads to 
an imbalance, with a relative excess of 
acetylcholine affecting motor control. 
Acetylcholine antagonists such as 
Artane provide some relief for a 
limited range of movement disorders, 
in particular tremor, although they are 
associated with side effects such as 
visual disturbance, confusion and 
hallucinations in elderly people, 
urinary retention and a dry mouth. 
They are usually prescribed in 
combination with levodopa to obtain 
maximum benefit. 
(4) Adamantane derivatives 
(glutamate blockers) 
Adamantane derivatives such as 
Amantadine are sometimes used as a 
first line of defence in the treatment of 
movement disorders in Parkinson's 
disease. Although they can initially 
have beneficial effects in the newly 
diagnosed, levodopa preparations are 
soon added when movement disorders 
become more troublesome. In addition 
to augmenting the presynaptic 
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figure 2. Common motor fluctuations observed in end-stage Parkinson's disease. 
synthesis and release of dopamine 
(Reynolds 1996), it appears that drugs 
such as Amantadine block overactivity 
of glutamate in the pathways from the 
striatum to the subthalamic nucleus 
and substantia nigra. Excessive levels of 
glutamate may act as a neurotoxin. 
Moreover, there is limited evidence 
that adamantane derivatives may have a 
neuroprotective effect, possibly by 
acting as anti-oxidants in the substantia 
nigra of the brainstem or via their anti-
glutamate effects (Reynolds 1996). 
(5) Neuroprotective agents 
Monoamine oxidase B (MAO B) 
inhibitors, such as selegiline (Eldepryl) 
block the catabolism of dopamine by 
microglia and astrocytes in the basal 
ganglia (Y oudim and Riederer 1997). 
As a result, the availability of dopamine 
at post-synaptic receptor sites is 
increased. This means that patients can 
sometimes be given lower doses of 
levodopa when selegeline is added to 
the medication regimen. These drugs 
may also have a neuroprotective effect, 
by reducing free radical formation and 
oxidation of substantia nigra neurones, 
although the recent "DATATOP" and 
UKPDRG drug trials failed to confirm 
this hypothesis (Lees 1995). In fact 
Lees (1995) found that selegiline in 
combination with levodopa was 
associated with an increase in mortality 
after three years of use. 
Motor fluctuations 
Despite the beneficial effects that 
levodopa, dopamine agonists and the 
adamantane derivatives can initially 
have on motor performance in 
Parkinson's disease, the benefits are 
shortlived (Barbeau 1974, Fahn 1974, 
Marsden and Parkes 1976). After a 
period of approximately five years, 
motor fluctuations develop in at least 
50 per cent of patients (Mouradian and 
Chase 1994) and increase in severity as 
the disease progresses. Initially the 
motor fluctuations present as a wearing 
off effect which occurs at the end of 
the medication dose. The person 
experiences a shift from near normal 
mobility (known as the "on" phase) to 
a state of immobility (known as the 
"off" phase - Figure 2). Later, as the 
disease progresses, abnormal 
involuntary extra movements 
(dyskinesias) can become evident. Most 
often these manifest as peak dose 
dyskinesias which are generally 
choreiform. Bi-phasic and end of dose 
dyskinesias are also reasonably 
common and can be choreiform or 
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Determine the 
purpose of 
measurement 
1 
Select 
appropriate level 
of measurement 
Disability Motor Movement 
Performance Disorders 
(tasks) 
~ 1 .~ 
Independence Walking Hypokinesia 
Function Turning Akinesia 
Well being Standing up Dyskinesia 
Activity level Sitting down Tremor 
Life satisfaction Rolling over Rigidity 
Prehension Postural instability 
Manipulation 
~ T / 
I Measure patient both "on" and "off" medication I 
t 
Repeat tests over time to clarify effects of medication, 
physiotherapy and natural progression of the disease 
Figure 3. Clinical decision making process used by physiotherapists to quantify motor 
fluctuations in Parkinson's disease. 
dystonic in type (Luquin et alI992, 
Muenter et al 1977 - Figure 2). Painful 
off-phase dystonias, often at night, can 
also occur in some people. Patients 
typically describe these as feeling like 
muscular cramps, low back pain or 
clawing of the toes. With long term 
use of dopamimetics over periods of 
10-30 years, different combinations of 
these motor fluctuations inevitably 
develop in the majority of people and, 
in some cases, can be just as disabling 
as the disease itself. 
Dyskinesias are thought to be 
mediated by D2 receptors on the 
striatal projections to the indirect 
pathway. However, the reason why 
peak dose dyskinesias and the on-off 
phenomenon eventually occur after 
prolonged use of Parkinson's disease 
medication is not completely clear. 
Possible explanations include that (i) 
drug induced changes in the striatum 
alter the sensitivity ofDI and D2 
receptors; (ii) pulsatile delivery and 
absorption of levodopa with oral doses 
leads to fluctuations in blood and brain 
concentrations of this drug (iii) there is 
a heightened sensitivity of the 
dopamine receptors in the striatum 
which appears to be due to functional 
denervation associated with prolonged 
depletion of dopamine cr ancovic and 
Marsden 1988). For a more detailed 
review of these issues, readers are 
referred to Fabbrini et al (1988), 
Marsden and Parkes (1986) and Nutt 
et al (1992). 
In evaluating motor fluctuations in 
Parkinson's disease, two components 
to the response to levodopa and 
apomorphine need to be considered. 
There is a short duration response, 
which occurs over a period of hours, 
and a long duration response which 
occurs over days and is presumably 
related to the cumulative effect of 
multiple doses. In de novo patients 
(drug naive with a short history of 
motor symptoms) the short duration 
response is present in some but not all 
cases (Gancher et al 1988) and the long 
duration response is present by 15 days 
of treatment (Quattrone et alI995). 
However, these responses can be 
difficult to detect clinically at the onset 
of drug treatment, as they usually 
occur subtly in people with an 
apparently stable response. As the 
disease progresses and the duration of 
drug treatment increases, the short 
duration responses to levodopa and 
apomorphine decrease. This means 
that the short duration effects of 
levodopa and apomorphine do not last 
as long, even though the size of the 
response (the difference between 
baseline performance and peak motor 
performance) remains constant as the 
disease progresses and fluctuations 
develop. Therefore the scheduling of 
drug administration might need to be 
altered, for example by changing 
administration from 6-hourly to 4-
hourly. The long duration response is 
much less studied and understood. It is 
generally measured as the deterioration 
in baseline motor performance after 
total drug withdrawal and represents at 
least one third of the total response to 
regular levodopa. The degree to which 
the long duration response changes 
with disease longevity and the duration 
of drug treatment is currently under 
investigation. The clinical implications 
of these findings for physiotherapists 
are that: (i) motor performance can 
vary according to when the person is 
observed in relation to the timing of 
medication and (ii) true baseline 
performance off drugs may not be 
reached for 1-2 weeks. 
Measuring motor fluctuations 
In addition to movement rehabilitation 
in Parkinson's disease, the role of the 
physiotherapist is to measure any 
motor fluctuations that occur 
according to the dosage, scheduling 
and type of medication prescribed. 
This role can include: 
• measuring the person's response 
capacity to drugs by conducting 
dose response trials (test doses) and 
plotting dose response curves for 
the short duration response; 
• determining the relative 
contributions of involuntary 
movements and hypokinesia/ 
akinesia to motor disability; 
• monitoring the person's motor 
response to medication during the 
course of physiotherapy and 
differentiating changes in motor 
performance resulting from 
physiotherapy and drugs; and 
• advising the health care team of 
the person's motor response to 
medications prescribed by the 
neurologist. 
Parkinson's disease is prevalent 
amongst elderly people and, with the 
rapid increase in the proportion of 
elderly people within the Australian 
population, the demand for 
physiotherapy assessment and 
treatment of movement disorders in 
Parkinson's disease has sharply 
increased. It is now commonplace for 
medical practitioners to refer patients 
to a physiotherapist for objective 
assessment of the person's motor 
response to medication, hence the 
ability to do this needs to be 
recognised as a basic competency. 
Most often the request from the 
neurologist is for a dose response trial 
(DRT) to evaluate the short duration 
response to a particular medication. In 
the Clinical Notes section of this 
edition of the Australian Journal of 
Physiotherapy, a step-by-step guide on 
how to perform a D RT is presented, 
illustrated by a case example. The 
remainder of this paper will focus on 
the process and tools that can be used 
by physiotherapists to monitor changes 
in motor performance that occur with 
Parkinson's disease medication. 
In charting the person's motor 
response to medication, the 
physiotherapist can monitor at the 
level of disability, motor function or 
movement disorders. A range of 
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disability scales are available that enable 
the clinician to quickly screen for gross 
motor status. Perhaps the best known 
of these is the Hoehn and Yahr (1967) 
scale, which provides a brief snapshot 
of the person's mobility and 
independence. The drawback of this 
scale is that it lacks sensitivity and is 
able to discriminate only dramatic 
changes in disability status. Therefore 
most clinicians also use either the 
Modified Webster scale (Kempster et 
aI1989), the Unified Parkinson's 
Disease Rating scale (UPDRS) (Fahn 
et aI1987), the North West University 
Disability scale (Canter 1961) or the 
Columbia scale (Yahr et a11969) to 
quickly screen for level of disability. 
Although the Functional Independence 
Measure (FIM) (Granger et a11986) 
has been shown to be a useful measure 
of disability in stroke patients and frail 
elderly people, it has not yet been 
validated in individuals with 
Parkinson's disease. Alternatively, the 
Human Activity Profile (Fix and 
Daughton 1988) can provide the 
clinician with a comprehensive 
summary of the person's motor activity 
which provides an indirect indication 
of disability status. 
In the clinical setting, 
physiotherapists most often measure 
change in motor peiformance by testing 
patients on several functional tasks 
such as walking, turning, standing up, 
sitting down, rolling over in bed, 
reaching, grasping, manipulating 
objects and writing (Table 3). The 
usual procedure is to time performance 
for a selection of these actions using a 
stopwatch and to observe for 
deviations in the person's movement 
kinematics. For analysing walking, the 
physiotherapist can also use a 
computerised stride analyser (CSA)t to 
quantify temporal and spatial 
parameters of gait, such as the velocity 
of walking, stride length, cadence and 
the duration of single limb support 
phases. Although high retest reliability 
has been established for CSA measures 
for patients in the "on" stage of the 
medication cycle (Morris et al 1996a 
and 1996b), the validity of visual 
observations and stopwatch measures 
for movement analysis in Parkinson's 
disease remains to be established. 
A further role of the physiotherapist 
is to quantify the severity of movement 
disorders in Parkinson's disease and to 
examine the degree to which 
movement disorders affect motor 
performance and functional ability. 
Whereas measures of gait hypokinesia 
and postural instablity have been 
examined for retest reliability, 
discriminant validity and predictive 
validity (Morris et al 1996a, 
Schenkman 1997, Smithson et al 
1998), tests of akinesia, rigidity, tremor 
and dyskinesia require further 
validation (Kennard et aI1984). Some 
clinicians rely on qualitative measures 
including visual observation, palpation 
and passive and active movement 
testing to make decisions about the 
severity of movement disorders and 
their response to Parkinson's disease 
medication. Qualitative measures of 
this type simply provide a clinical 
impression and do not yield data on 
the severity of specific movement 
disorders or their impact on task 
performance. 
The combination of tests used to 
quantify motor status will vary from 
individual to individual, according to 
the person's problems and the aims of 
the measurement process. If, for 
example, the aim is to quantify whether 
postural instability changes according 
to levodopa status, the physiotherapist 
might choose to use the Pastor test 
(Pastor et al 1996) combined with tests 
of steady standing and the Functional 
Reach test (see Table 3) at peak dose 
and again at the end of dose. On the 
other hand, if the primary aim is to 
chart upper limb status, the clinician 
would typically observe for tremor, 
hypokinesia and dyskinesia; test the 
person on the Purdue Pegboard (Tiffin 
1979); obtain a handwriting sample; 
and observe the person performing 
functional upper limb tasks such as 
picking up the dosette box from the 
bedside table and removing the 
medication. 
As well as determining an appropriate 
level of analysis (disability, motor 
function or movement disorders), the 
physiotherapist needs to carefully 
consider the timing of measurement. 
To be able to detect change in 
performance, it is important to first 
have baseline measures of stability 
against which future performance can 
be compared. In Parkinson's disease, 
two baselines need to be charted: (i) an 
on-phase baseline, representing the 
person's typical performance at peak 
dose in the medication cycle; and (ii) 
an off-phase baseline, representing the 
person's typical performance at the end 
of the dose, when blood concentrations 
of medication are low. For people on a 
4-hourly medication regimen it is 
customary for the on-phase 
measurements to be obtained one hour 
after the Parkinson's disease 
medication and the off-phase measures 
to be obtained half an hour prior to the 
next dose. Due to the typical 
fluctuations in performance, usually 
three trials of a given test are needed to 
establish a reliable baseline sample, 
such as three 10m walking trials, three 
handwriting samples or three trials on 
the Purdue Pegboard test. It is useful 
to document the assessment findings 
using colour coded assessment forms, 
for example a green assessment form 
for on-phase readings and a pink form 
for the off-phase readings (Morris and 
Iansek 1997). 
Fluctuations in motor performance 
can be measured: (i) within a single 
Parkinson's disease medication cycle, 
typically 4-6 hours duration; (ii) across 
a 12 or 24 hour period; (iii) across five 
days (one working week) of an 
inpatient stay; (iv) across longer 
periods ranging from weeks to months. 
When testing within a single cycle, 
frequent sampling of motor 
performance using a small battery of 
tests is required. For example, at the 
Kingston Centre in Melbourne, the 
response to standard levodopa is often 
charted by testing the person every 15 
minutes using the 10m walk, Timed-
Up-And-Go test and Purdue Pegboard 
test. The first trial commences half an 
hour before the medication is taken, 
and then subsequent trials occur every 
15 minutes for the duration of that 
cycle (frequently 4 hours). If the aim is 
to evaluate motor fluctuations 
throughout the course of a day, less 
frequent sampling is needed, and the 
physiotherapist can use more lengthy 
testing procedures if required. The 
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person could, for example, be 
measured every two hours 
commencing at 8 am using the CSA, a 
battery of postural stability tests 
(Smithson et al 1998), the Purdue 
Pegboard test and a dyskinesia rating 
scale such as in the UPDRS (Fahn et al 
1987). When charting motor 
fluctuations across periods ranging 
from one week to a number of years, it is 
customary for measures to be obtained 
on each occasion in relation to the on 
and off-phases of the mid-morning 
dose of medication (which is often 
taken at 10 am). As discussed 
previously, the selection of which 
clinical tests to include in the battery 
for that person will depend on the 
major movement disorders that limit 
functional performance. 
The clinical decision making process 
used by physiotherapists to determine 
the appropriate level of measurement 
is detailed in Figure 3. The figure 
highlights the need to repeat tests over 
time in order to chart the patient's 
progress. There may be a further need 
to differentiate the effects of 
medication from physiotherapy and 
the natural progression of the disease. 
This is complex and can be tackled in a 
variety of ways. As a guide, it should be 
kept in mind that changes associated 
with medication are often large in 
magnitude, occur rapidly within the 
first hour after it is administered, have 
a short duration response of 
approximately 4-6 hours and a much 
smaller long duration response for up 
to 15 days. A DRT is the best way to 
measure the short duration response of 
medication; the long duration response 
can be determined only by a "drug 
holiday" which is seldom considered 
necessary. To differentiate the short-
term effects of physiotherapy from 
medication, motor performance is first 
tested at peak dose of the medication 
cycle then training immediately occurs. 
Training for a motor function such as 
walking or standing up may take 20-40 
minutes and is followed by prompt re-
measurement before the off-phase 
occurs. This procedure reveals the 
contribution of physiotherapy over and 
above the effects of medication. 
Alternatively, the short-term effects of 
physiotherapy can be assessed by 
measuring motor performance before 
and after a training session prior to the 
person's first morning dose of 
antiparkinsonian medication. Although 
this more clearly differentiates the 
effects of physiotherapy and 
medication, patient compliance may be 
low, as testing needs to occur before 
the first dose (usually at 6 am or 8 am) 
and before breakfast is consumed. This 
procedure is therefore most suitable 
for inpatients rather than patients 
resident in the community. To 
ascertain the natural progression of the 
disease, patients are usually tested at 3-
monthly intervals under optimal 
conditions (at peak dose of the 10 am 
medication after physiotherapy 
training) as well as in the off phase of 
the lOam dose without physiotherapy 
(when physiotherapy and medication 
are less likely to obscure effects due to 
disease progression). Alternatively they 
can be tested at 3-monthly intervals 
prior to the first morning dose of 
medication. 
In summary, there is an increasing 
need for physiotherapists to quantify 
changes in motor performance that 
occur with Parkinson's disease 
medication and to communicate 
findings to neurologists and other 
health professionals. In order to do this 
competently, there is a need to have up 
to date knowledge of the 
pathophysiology of Parkinson's 
disease, the mode of action of the 
range of medications available as well 
as skills in objectively measuring motor 
fluctuations. By carefully documenting 
changes in performance over time, the 
most effective treatment program can 
be implemented by the 
interprofessional team. 
t Clinical Stride Analyser: A 
computerised footswitch system 
that enables measurement of the 
temporal and spatial parameters of 
gait. 
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